Which Treatment Pathway Suits Your Weight Management Goals?
Understanding How to Switch From Wegovy to Mounjaro: Mechanism Differences
When considering how to switch from Wegovy to Mounjaro, the fundamental difference lies in their mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, working primarily on brain appetite centres to reduce hunger and promote satiety. Mounjaro, containing tirzepatide, takes a dual approach by targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously, potentially offering enhanced metabolic effects through this combined pathway activation.
This dual-action mechanism of Mounjaro may explain why some patients explore how to switch from Wegovy to Mounjaro after experiencing plateau effects or seeking different therapeutic outcomes. Both prescription-only medicines require clinical assessment and work alongside lifestyle modifications, but their different receptor targeting profiles mean individual responses can vary significantly. Your prescriber can evaluate whether transitioning between these treatments aligns with your weight management objectives and medical history.
Wegovy vs Mounjaro Pricing: Complete Cost Comparison
Understanding the financial implications when considering how to switch from Wegovy to Mounjaro involves comparing our transparent pricing structures. Wegovy follows a 5-dose escalation: 0.25mg starter dose £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99) to maintenance 2.4mg (£209.99). New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to access these final prices. Our Getting Started bundles offer convenience, such as the Intro Duo combining your first two months (0.25mg & 0.5mg) for £169.99.
Mounjaro pricing reflects its different dosing schedule, with six available strengths from 2.5mg through to 15mg maintenance doses. Both treatments are available from our GPhC-registered pharmacy (#9012878), eliminating the need to switch providers when exploring how to switch from Wegovy to Mounjaro. Our clinical team ensures seamless transitions between treatments whilst maintaining consistent pharmaceutical standards and cold-chain delivery protocols throughout your weight management journey.
Clinical Evidence: STEP Trials and Treatment Efficacy
The clinical foundation for understanding how to switch from Wegovy to Mounjaro rests on robust trial data from different study programmes. Wegovy's evidence comes from the comprehensive STEP trial series, where patients taking semaglutide alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in STEP 1, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP programme demonstrated sustained results, with STEP 5 showing 15.2% weight reduction maintained at two years.
Mounjaro's clinical profile emerges from the SURMOUNT trials, evaluating tirzepatide's dual GIP/GLP-1 mechanism in weight management contexts. Both treatments represent evidence-based approaches to prescription weight management, though direct head-to-head comparisons aren't available due to different trial designs and populations. When considering how to switch from Wegovy to Mounjaro, your prescriber will evaluate individual trial outcomes against your personal medical history and treatment response patterns.
How Wegovy Works: GLP-1 Receptor Mechanism
Wegovy's semaglutide operates as a GLP-1 receptor agonist, mimicking the action of naturally occurring incretin hormones that regulate appetite and glucose metabolism. Once injected weekly via the FlexTouch pen device, semaglutide binds to GLP-1 receptors in the brain, particularly within hypothalamic regions controlling hunger and satiety signals. This receptor activation promotes feelings of fullness after smaller meals, reduces overall appetite, and may diminish food cravings by modulating reward pathways associated with eating behaviours. The medication slows gastric emptying, extending the duration of meal satisfaction and contributing to reduced caloric intake when combined with dietary modifications. Understanding this mechanism helps explain why some patients explore how to switch from Wegovy to Mounjaro - seeking different receptor targeting approaches for their individual weight management needs.
EverydayMeds Ordering Process: Assessment to Delivery
Beginning your weight management journey or exploring how to switch from Wegovy to Mounjaro starts with our streamlined 3-minute online clinical assessment, designed to capture essential medical information for prescriber review. Following assessment submission, our qualified prescribers evaluate your clinical suitability within standard 3 working days, or 24 hours with express review options for urgent requirements. Once approved, your prescription-only medicine is prepared by our GPhC-registered pharmacy team (#9012878) using pharmaceutical-grade cold-chain protocols to maintain medication integrity. Next-day delivery ensures rapid treatment commencement, with temperature-controlled packaging protecting your medication throughout transit. Our clinical support team remains available for questions about dose escalation, storage requirements, or treatment transitions between Wegovy and Mounjaro options.
Storage and Practical Considerations: Wegovy vs Mounjaro
Storage requirements present a practical advantage when considering how to switch from Wegovy to Mounjaro, particularly for frequent travelers or those with limited refrigeration access. Wegovy pens maintain stability for up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both treatments require initial refrigerated storage at 2-8°C before first use, but Wegovy's extended temperature tolerance offers greater flexibility for holidays, business travel, or temporary storage challenges. The FlexTouch pen delivery system provides consistent dosing accuracy across the 5-dose escalation schedule from 0.25mg starter through to 2.4mg maintenance. Dose escalation cannot be skipped, ensuring optimal tolerability whilst achieving therapeutic effectiveness. Both medications follow structured titration protocols designed to minimise gastrointestinal side effects whilst maximising weight management benefits.
Treatment Transition Strategies: From Wegovy to Mounjaro
Successfully managing how to switch from Wegovy to Mounjaro requires careful clinical oversight to ensure treatment continuity without compromising weight management progress. The transition typically involves a washout period allowing complete semaglutide clearance before initiating tirzepatide's dual-receptor approach, though specific timing depends on individual clinical factors and current dose levels. Your prescriber will evaluate plateau effects, side effect profiles, and therapeutic goals when determining optimal switching protocols.
Mounjaro's starting dose selection considers your previous Wegovy experience, current tolerance levels, and weight loss trajectory to date. The dual GIP/GLP-1 mechanism may offer renewed therapeutic momentum for patients experiencing diminished Wegovy effectiveness, whilst the different side effect profile might suit those experiencing persistent gastrointestinal effects. Both treatments remain available through EverydayMeds, ensuring seamless pharmaceutical continuity throughout your transition process without requiring new pharmacy relationships or clinical assessments.
Making Your Treatment Decision: Expert Clinical Support
Your decision regarding how to switch from Wegovy to Mounjaro benefits from expert clinical guidance weighing mechanism differences, individual response patterns, and long-term weight management objectives. Both semaglutide and tirzepatide represent clinically proven approaches to prescription weight management, each offering distinct advantages through their receptor targeting profiles. Wegovy's established GLP-1 pathway provides predictable appetite reduction and satiety enhancement, whilst Mounjaro's innovative dual-receptor approach may offer enhanced metabolic benefits through combined GIP/GLP-1 activation. Our clinical team evaluates your complete medical picture, treatment history, and personal preferences to recommend the most suitable therapeutic approach. Whether continuing Wegovy or exploring Mounjaro's dual-action benefits, both treatments are available from our GPhC-registered pharmacy with consistent clinical support, transparent pricing, and reliable next-day delivery. Apply code FIRST40 for new customer pricing or DOSE25 for returning patients when ordering through https://everydaymeds.co.uk/collections/weight-loss to begin your personalised weight management journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
